Is MGX or MRNA more profitable?

Moderna has a net margin of -143.55% compared to Metagenomi's net margin of -384.61%. Moderna's return on equity of -26.64% beat Metagenomi's return on equity. Company Net Margins Return on Equity Return on Assets Metagenomi -384.61% -51.23% -36.62% Moderna -143.55% -26.64% -19.32%

Does the media prefer MGX or MRNA?

In the previous week, Moderna had 20 more articles in the media than Metagenomi. MarketBeat recorded 23 mentions for Moderna and 3 mentions for Metagenomi. Moderna's average media sentiment score of 0.82 beat Metagenomi's score of 0.75 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metagenomi 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 10 Very Positive mention(s) 6 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ORMP or MGX?

Metagenomi has a consensus target price of $7.00, suggesting a potential upside of 430.30%. Given Metagenomi's stronger consensus rating and higher probable upside, analysts clearly believe Metagenomi is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Metagenomi 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Does the media refer more to PYXS or MGX?

In the previous week, Pyxis Oncology had 12 more articles in the media than Metagenomi. MarketBeat recorded 15 mentions for Pyxis Oncology and 3 mentions for Metagenomi. Metagenomi's average media sentiment score of 0.75 beat Pyxis Oncology's score of -0.54 indicating that Metagenomi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pyxis Oncology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Metagenomi 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Metagenomi (MGX) Competitors

$1.32 +0.05 (+3.94%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$1.32 0.00 (-0.15%)

As of 07:35 AM Eastern

Compare

MGX vs. MRNA, ORMP, PLX, LFCR, and PYXS

Should you buy Metagenomi stock or one of its competitors? MarketBeat compares Metagenomi with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Metagenomi include Moderna (MRNA), Oramed Pharmaceuticals (ORMP), Protalix BioTherapeutics (PLX), Lifecore Biomedical (LFCR), and Pyxis Oncology (PYXS). These companies are all part of the "pharmaceutical products" industry.

How does Metagenomi compare to Moderna?

Metagenomi (NASDAQ:MGX) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Metagenomi has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	1.97	-$87.87M	-$2.30	N/A
Moderna	$1.94B	13.68	-$2.82B	-$8.15	N/A

Moderna has a net margin of -143.55% compared to Metagenomi's net margin of -384.61%. Moderna's return on equity of -26.64% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-51.23%	-36.62%
Moderna	-143.55%	-26.64%	-19.32%

In the previous week, Moderna had 20 more articles in the media than Metagenomi. MarketBeat recorded 23 mentions for Moderna and 3 mentions for Metagenomi. Moderna's average media sentiment score of 0.82 beat Metagenomi's score of 0.75 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Metagenomi	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	10 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Metagenomi currently has a consensus price target of $7.00, indicating a potential upside of 430.30%. Moderna has a consensus price target of $38.27, indicating a potential downside of 42.89%. Given Metagenomi's stronger consensus rating and higher probable upside, research analysts clearly believe Metagenomi is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Moderna	5 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.82

75.3% of Moderna shares are owned by institutional investors. 12.5% of Metagenomi shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Metagenomi has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, Moderna has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

Summary

Moderna beats Metagenomi on 9 of the 17 factors compared between the two stocks.

How does Metagenomi compare to Oramed Pharmaceuticals?

Oramed Pharmaceuticals (NASDAQ:ORMP) and Metagenomi (NASDAQ:MGX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

In the previous week, Metagenomi had 2 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 3 mentions for Metagenomi and 1 mentions for Oramed Pharmaceuticals. Oramed Pharmaceuticals' average media sentiment score of 1.87 beat Metagenomi's score of 0.75 indicating that Oramed Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Oramed Pharmaceuticals	Very Positive
Metagenomi	Positive

Oramed Pharmaceuticals has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Oramed Pharmaceuticals' return on equity of -5.37% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.37%	-4.83%
Metagenomi	-384.61%	-51.23%	-36.62%

Oramed Pharmaceuticals has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market. Comparatively, Metagenomi has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 17.8% of Oramed Pharmaceuticals shares are held by company insiders. Comparatively, 12.5% of Metagenomi shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Oramed Pharmaceuticals has higher earnings, but lower revenue than Metagenomi. Metagenomi is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$2M	80.84	$64.05M	$2.59	1.53
Metagenomi	$25.21M	1.97	-$87.87M	-$2.30	N/A

Metagenomi has a consensus target price of $7.00, suggesting a potential upside of 430.30%. Given Metagenomi's stronger consensus rating and higher probable upside, analysts clearly believe Metagenomi is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Oramed Pharmaceuticals beats Metagenomi on 11 of the 17 factors compared between the two stocks.

How does Metagenomi compare to Protalix BioTherapeutics?

Protalix BioTherapeutics (NYSE:PLX) and Metagenomi (NASDAQ:MGX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Protalix BioTherapeutics has higher revenue and earnings than Metagenomi. Metagenomi is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$76.38M	2.52	$8.31M	$0.18	13.28
Metagenomi	$25.21M	1.97	-$87.87M	-$2.30	N/A

Protalix BioTherapeutics currently has a consensus price target of $12.00, indicating a potential upside of 402.09%. Metagenomi has a consensus price target of $7.00, indicating a potential upside of 430.30%. Given Metagenomi's higher probable upside, analysts plainly believe Metagenomi is more favorable than Protalix BioTherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Metagenomi had 3 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 3 mentions for Metagenomi and 0 mentions for Protalix BioTherapeutics. Metagenomi's average media sentiment score of 0.75 beat Protalix BioTherapeutics' score of 0.00 indicating that Metagenomi is being referred to more favorably in the news media.

Company	Overall Sentiment
Protalix BioTherapeutics	Neutral
Metagenomi	Positive

Protalix BioTherapeutics has a net margin of -21.03% compared to Metagenomi's net margin of -384.61%. Protalix BioTherapeutics' return on equity of -30.89% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Metagenomi	-384.61%	-51.23%	-36.62%

16.5% of Protalix BioTherapeutics shares are held by institutional investors. 6.7% of Protalix BioTherapeutics shares are held by company insiders. Comparatively, 12.5% of Metagenomi shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Protalix BioTherapeutics beats Metagenomi on 9 of the 16 factors compared between the two stocks.

How does Metagenomi compare to Lifecore Biomedical?

Lifecore Biomedical (NASDAQ:LFCR) and Metagenomi (NASDAQ:MGX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

Lifecore Biomedical has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market. Comparatively, Metagenomi has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market.

In the previous week, Metagenomi had 2 more articles in the media than Lifecore Biomedical. MarketBeat recorded 3 mentions for Metagenomi and 1 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 1.87 beat Metagenomi's score of 0.75 indicating that Lifecore Biomedical is being referred to more favorably in the media.

Company	Overall Sentiment
Lifecore Biomedical	Very Positive
Metagenomi	Positive

Lifecore Biomedical has higher revenue and earnings than Metagenomi. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.35	-$35.26M	-$0.94	N/A
Metagenomi	$25.21M	1.97	-$87.87M	-$2.30	N/A

Lifecore Biomedical has a net margin of -25.43% compared to Metagenomi's net margin of -384.61%. Lifecore Biomedical's return on equity of 0.00% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-25.43%	N/A	-14.40%
Metagenomi	-384.61%	-51.23%	-36.62%

Lifecore Biomedical currently has a consensus target price of $6.50, indicating a potential upside of 40.39%. Metagenomi has a consensus target price of $7.00, indicating a potential upside of 430.30%. Given Metagenomi's stronger consensus rating and higher possible upside, analysts clearly believe Metagenomi is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

83.4% of Lifecore Biomedical shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by company insiders. Comparatively, 12.5% of Metagenomi shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Lifecore Biomedical beats Metagenomi on 10 of the 17 factors compared between the two stocks.

How does Metagenomi compare to Pyxis Oncology?

Pyxis Oncology (NASDAQ:PYXS) and Metagenomi (NASDAQ:MGX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

39.1% of Pyxis Oncology shares are owned by institutional investors. 5.7% of Pyxis Oncology shares are owned by insiders. Comparatively, 12.5% of Metagenomi shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Pyxis Oncology has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -51.23% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-135.60%	-85.00%
Metagenomi	-384.61%	-51.23%	-36.62%

Pyxis Oncology has higher earnings, but lower revenue than Metagenomi. Pyxis Oncology is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	11.15	-$79.62M	-$1.31	N/A
Metagenomi	$25.21M	1.97	-$87.87M	-$2.30	N/A

Pyxis Oncology has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market. Comparatively, Metagenomi has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

In the previous week, Pyxis Oncology had 12 more articles in the media than Metagenomi. MarketBeat recorded 15 mentions for Pyxis Oncology and 3 mentions for Metagenomi. Metagenomi's average media sentiment score of 0.75 beat Pyxis Oncology's score of -0.54 indicating that Metagenomi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pyxis Oncology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Metagenomi	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Pyxis Oncology presently has a consensus price target of $6.86, suggesting a potential upside of 181.03%. Metagenomi has a consensus price target of $7.00, suggesting a potential upside of 430.30%. Given Metagenomi's stronger consensus rating and higher probable upside, analysts clearly believe Metagenomi is more favorable than Pyxis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Metagenomi beats Pyxis Oncology on 9 of the 17 factors compared between the two stocks.

Get Metagenomi News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MGX vs. The Competition

Export

Metric	Metagenomi	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$47.81M	$3.05B	$7.05B	$12.61B
Dividend Yield	N/A	2.06%	2.68%	8.00%
P/E Ratio	-0.57	19.17	27.11	24.26
Price / Sales	1.97	838.79	589.96	117.88
Price / Cash	N/A	56.80	29.22	49.36
Price / Book	0.31	4.22	10.74	6.29
Net Income	-$87.87M	$64.26M	$3.58B	$330.66M
7 Day Performance	N/A	-3.58%	-2.11%	-1.35%
1 Month Performance	10.00%	2.12%	3.27%	-0.64%
1 Year Performance	-41.33%	20.35%	26.31%	19.08%

Metagenomi Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MGX Metagenomi	3.1006 of 5 stars	$1.32 +3.9%	$7.00 +430.3%	-39.4%	$47.81M	$25.21M	N/A	236	Analyst Downgrade High Trading Volume
MRNA Moderna	1.8647 of 5 stars	$79.40 -2.9%	$37.87 -52.3%	+99.2%	$31.48B	$1.94B	N/A	4,700
ORMP Oramed Pharmaceuticals	2.405 of 5 stars	$4.54 -0.7%	N/A	+85.4%	$185.82M	$2M	1.75	10	Positive News
PLX Protalix BioTherapeutics	2.4845 of 5 stars	$2.31 +0.2%	$12.00 +420.6%	+69.5%	$185.64M	$76.38M	N/A	200
LFCR Lifecore Biomedical	1.9679 of 5 stars	$4.88 -3.5%	$6.50 +33.3%	-44.2%	$184.84M	$128.87M	N/A	690

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MGX) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Metagenomi (MGX) Competitors

MGX vs. MRNA, ORMP, PLX, LFCR, and PYXS

How does Metagenomi compare to Moderna?

Summary

How does Metagenomi compare to Oramed Pharmaceuticals?

Summary

How does Metagenomi compare to Protalix BioTherapeutics?

Summary

How does Metagenomi compare to Lifecore Biomedical?

Summary

How does Metagenomi compare to Pyxis Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGX vs. The Competition

Metagenomi Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Metagenomi (MGX) Competitors

MGX vs. MRNA, ORMP, PLX, LFCR, and PYXS

How does Metagenomi compare to Moderna?

Which has stronger earnings & valuation, MGX or MRNA?

Is MGX or MRNA more profitable?

Does the media prefer MGX or MRNA?

Do analysts recommend MGX or MRNA?

Do institutionals & insiders believe in MGX or MRNA?

Which has more volatility and risk, MGX or MRNA?

Summary

How does Metagenomi compare to Oramed Pharmaceuticals?

Does the media refer more to ORMP or MGX?

Is ORMP or MGX more profitable?

Which has more risk & volatility, ORMP or MGX?

Do institutionals and insiders hold more shares of ORMP or MGX?

Which has preferable earnings & valuation, ORMP or MGX?

Do analysts recommend ORMP or MGX?

Summary

How does Metagenomi compare to Protalix BioTherapeutics?

Which has higher earnings and valuation, PLX or MGX?

Do analysts prefer PLX or MGX?

Does the media refer more to PLX or MGX?

Is PLX or MGX more profitable?

Do institutionals and insiders believe in PLX or MGX?

Summary

How does Metagenomi compare to Lifecore Biomedical?

Which has more risk & volatility, LFCR or MGX?

Does the media favor LFCR or MGX?

Which has stronger earnings and valuation, LFCR or MGX?

Is LFCR or MGX more profitable?

Do analysts rate LFCR or MGX?

Do insiders & institutionals believe in LFCR or MGX?

Summary

How does Metagenomi compare to Pyxis Oncology?

Do institutionals and insiders hold more shares of PYXS or MGX?

Is PYXS or MGX more profitable?

Which has stronger earnings & valuation, PYXS or MGX?

Which has more volatility & risk, PYXS or MGX?

Does the media refer more to PYXS or MGX?

Do analysts recommend PYXS or MGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGX vs. The Competition

Metagenomi Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools